Illinois's new WOPR Act bans AI chatbots from delivering psychotherapy or clinical decisions, with fines up to $10,000 per violation, making it the latest of four states to restrict AI mental-health tools in 2026.
DermaSensor's handheld AI device, cleared by the FDA for primary-care use, detects the three most common skin cancers with 96% sensitivity, aiming to catch melanoma earlier outside dermatology offices.
Aureka Biotechnologies raised $100 million to build a 'biological world model' that simulates antibody design rather than just predicting protein structure, entering a crowded AI drug discovery funding field dominated by billion-dollar players.
Alphabet's AI drug discovery spinout Isomorphic Labs closed a $2.1 billion Series B led by Thrive Capital in May 2026, one of the largest financings ever for an AI-first biotech, as it races toward its first human clinical trials by late 2026.
Woebot Health shut down its consumer AI therapy chatbot after years pursuing FDA marketing authorization it never received, with its founder blaming a regulatory process too slow for fast-moving AI — a cautionary tale now shadowing the whole AI mental health industry.
Chai Discovery raised a $400 million Series C at a $3.8 billion valuation to scale its generative AI models for designing antibodies and proteins, building on paid discovery partnerships with Eli Lilly, Pfizer and Novartis.
A phishing attack on healthcare AI vendor Xsolis exposed sensitive data on 1.4 million patients tied to clients including Humana and Mayo Clinic Health System, with at least eight health systems confirming their patients were affected.
AI companion robot Abi, piloted in an Australian senior care home in 2025, is now coming to US facilities amid a crowded field of rivals and a $173,000 institutional robot called Moya — raising both promising acceptance rates and sharp ethical questions about cost, data, and human connection.
Northwestern University engineers printed flexible artificial neurons from graphene and molybdenum disulfide that successfully triggered responses in living mouse brain tissue, an early step toward energy-efficient neuromorphic computing and future brain-machine interfaces.
Deep Origin says its AI platform, which blends physics-based simulation with machine learning, found viable cancer immunotherapy drug candidates at a 31% hit rate, nearly 100 times the industry's typical rate, though no AI-designed drug has yet won regulatory approval.